These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35928818)

  • 1. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
    Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
    Front Immunol; 2022; 13():946692. PubMed ID: 35928818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation.
    Zhao W; Chang Y; Wu Z; Jiang X; Li Y; Xie R; Fu D; Sun C; Gao J
    PeerJ; 2023; 11():e15703. PubMed ID: 37483962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma.
    Jiang F; Liang M; Huang X; Shi W; Wang Y
    PeerJ; 2021; 9():e11697. PubMed ID: 34268011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    Ming Y; Luo C; Ji B; Cheng J
    BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
    Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
    Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.
    Ding M; Li YA; Lu Z; Hou G
    Biomed Res Int; 2022; 2022():1734847. PubMed ID: 35198632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
    Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
    CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
    Chen Y; Li Q; Zhang J; Gu R; Li K; Zhao G; Yuan H; Feng T; Ou D; Lin P
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2020 Jun; 37(3):469-479. PubMed ID: 32597089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
    Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
    Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOL4, a Novel Immune-Related Prognostic Biomarker for Glioma.
    Zhu H; Hu X; Feng S; Li Y; Zhang Y; Qiu S; Chen R; Ye Y; Gu L; Jian Z; Xu X; Xiong X
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233633
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.